Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TTR-H5223 | Human | Human Transthyretin / Prealbumin Protein, His Tag | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Patisiran | SAR-438037; GENZ-438027; ALN-TTR02; ALN-18328 | Approved | Alnylam Pharmaceuticals Inc | Onpattro | Japan | Transthyretin amyloidosis | Alnylam Pharmaceuticals Inc | 2018-08-10 | Amyloid Neuropathies, Familial; Amyloidosis, Familial; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies | Details |
Inotersen sodium | ISIS-420915; GSK-2998728 | Approved | Ionis Pharmaceuticals Inc | Tegsedi | United States | Transthyretin amyloidosis | Ptc Therapeutics Inc, Akcea Therapeutics Inc | 2018-07-05 | Amyloid Neuropathies, Familial; Adenomatous Polyposis Coli; Amyloidosis; Transthyretin amyloidosis | Details |
Tafamidis Meglumine | PF-6291826; Fx-1006A; PF-06291826; FX-1006A | Approved | Pfizer Inc | 维达全, Vyndaqel, Vyndamax, Vyndaqel/Vyndamax | Mainland China | Transthyretin amyloidosis; Amyloid Neuropathies | Pfizer Europe Ma Eeig | 2011-11-16 | Amyloid Neuropathies, Familial; Immunoglobulin Light-chain Amyloidosis; Heart Diseases; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NI-006 | NI-006 | Phase 1 Clinical | Neurimmune | Cardiomyopathies; Transthyretin amyloidosis | Details |
NTLA-2001 | NTLA-2001 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc | Amyloidosis, Familial; Cardiomyopathies; Amyloid Neuropathies; Transthyretin amyloidosis | Details |
Eplontersen | IONIS-TTR-LRx; ION-682884; AKCEA-TTR-LRx; ION-TTR-LRx | Phase 3 Clinical | Ionis Pharmaceuticals Inc | Amyloid Neuropathies, Familial; Cardiomyopathies; Transthyretin amyloidosis | Details |
Acoramidis | AG-10; ALXN-2060; BBP-265 | Phase 3 Clinical | Stanford University, Bridgebio Pharma Inc | Amyloidosis, Familial; Heart Diseases; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies | Details |
This web search service is supported by Google Inc.